Allogene Therapeutics, Inc. — Director's Dealing 2020

Aug 14, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Allogene Therapeutics, Inc. (ALLO)
CIK: 0001737287
Period of Report: 2020-08-13

Reporting Person: MOORE ALISON (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-08-13	Common Stock	M	32451	$2.27	Acquired	126272	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-08-13	Stock Option (Right to Buy)	$2.27	M	32451	Disposed	2028-06-25	Common Stock (32451)	Direct

Footnotes

F1: One-fourth of the 892,500 shares subject to the stock option vested on June 1, 2019, and the remaining shares vest in 36 successive equal monthly installments thereafter.